These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37625266)

  • 1. Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.
    Swanstrom AE; Gorelick RJ; Welker JL; Schmidt F; Lu B; Wang K; Rowe W; Breed MW; Killoran KE; Kramer JA; Donohue D; Roser JD; Bieniasz PD; Hatziioannou T; Pyle C; Thomas JA; Trubey CM; Zheng J; Blair W; Yant SR; Lifson JD; Del Prete GQ
    EBioMedicine; 2023 Sep; 95():104764. PubMed ID: 37625266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model.
    Bekerman E; Yant SR; VanderVeen L; Hansen D; Lu B; Rowe W; Wang K; Callebaut C
    J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
    Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
    Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
    Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
    mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host.
    Schmidt F; Keele BF; Del Prete GQ; Voronin D; Fennessey CM; Soll S; Kane M; Raymond A; Gifford RJ; KewalRamani V; Lifson JD; Bieniasz PD; Hatziioannou T
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10504-10509. PubMed ID: 31048506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
    Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
    Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS.
    Swanstrom AE; Jacques A; Del Prete GQ; Bieniasz P; Hatziioannou T; Gorelick R; Lifson JD
    AIDS Res Hum Retroviruses; 2019 May; 35(5):473-476. PubMed ID: 30632394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
    Margot N; Ram R; Rhee M; Callebaut C
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A macaque model of HIV-1 infection.
    Hatziioannou T; Ambrose Z; Chung NP; Piatak M; Yuan F; Trubey CM; Coalter V; Kiser R; Schneider D; Smedley J; Pung R; Gathuka M; Estes JD; Veazey RS; KewalRamani VN; Lifson JD; Bieniasz PD
    Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4425-9. PubMed ID: 19255423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.
    Vidal SJ; Bekerman E; Hansen D; Lu B; Wang K; Mwangi J; Rowe W; Campigotto F; Zheng J; Kato D; Chandrashekar A; Barrett J; Patel S; Wan H; Anioke T; Mercado NB; Nkolola JP; Ferguson MJ; Rinaldi WJ; Callebaut C; Blair W; Cihlar T; Geleziunas R; Yant SR; Barouch DH
    Nature; 2022 Jan; 601(7894):612-616. PubMed ID: 34875675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
    Prather C; Lee A; Yen C
    Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
    Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
    Bekerman E; Cox S; Babusis D; Campigotto F; Das M; Barouch DH; Cihlar T; Callebaut C
    J Antimicrob Chemother; 2021 Feb; 76(3):692-698. PubMed ID: 33202006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.